Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2014 | Original Article

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients

Authors: IL Han Choo, Stephen F. Carter, Michael L. Schöll, Agneta Nordberg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2014

Abstract

Purpose

The Alzheimer’s disease (AD) pathology is characterized by fibrillar amyloid deposits and neurofibrillary tangles, as well as the activation of astrocytosis, microglia activation, atrophy, dysfunctional synapse, and cognitive impairments. The aim of this study was to test the hypothesis that astrocytosis is correlated with reduced gray matter density in prodromal AD.

Methods

Twenty patients with AD or mild cognitive impairment (MCI) underwent multi-tracer positron emission tomography (PET) studies with ¹¹C-Pittsburgh compound B (¹¹C-PIB), ¹⁸ F-Fluorodeoxyglucose (¹⁸ F-FDG), and ¹¹C-deuterium-L-deprenyl (¹¹C-DED) PET imaging, as well as magnetic resonance imaging (MRI) scanning, cerebrospinal fluid (CSF) biomarker analysis, and neuropsychological assessments. The parahippocampus was selected as a region of interest, and each value was calculated for four different imaging modalities. Correlation analysis was applied between DED slope values and gray matter (GM) densities by MRI. To further explore possible relationships, correlation analyses were performed between the different variables, including the CSF biomarker.

Results

A significant negative correlation was obtained between DED slope values and GM density in the parahippocampus in PIB-positive (PIB + ve) MCI patients (p = 0.025) (prodromal AD). Furthermore, in exploratory analyses, a positive correlation was observed between PIB-PET retention and DED binding in AD patients (p = 0.014), and a negative correlation was observed between PIB retention and CSF Aβ42 levels in MCI patients (p = 0.021), while the GM density and CSF total tau levels were negatively correlated in both PIB + ve MCI (p = 0.002) and MCI patients (p = 0.001). No significant correlation was observed with FDG-PET and with any of the other PET, MRI, or CSF biomarkers.

Conclusions

High astrocytosis levels in the parahippocampus of PIB + ve MCI (prodromal AD) patients suggest an early preclinical influence on cellular tissue loss. The lack of correlation between astrocytosis and CSF tau levels, and a positive correlation between astrocytosis and fibrillar amyloid deposition in clinical demented AD together indicate that parahippocampal astrocytosis might have some causality within the amyloid pathology.

Available only for authorised users

Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2009;118:475–85. doi:10.1007/s00401-009-0556-6.PubMedCrossRefPubMedCentral

Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer’s disease. Neurotherapeutics. 2010;7:399–412. doi:10.1016/j.nurt.2010.05.017.PubMedCrossRef

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15–30.PubMedCrossRef

Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience. 1996;70:755–74. doi:10.1016/S0306-4522(96)83013-2.PubMedCrossRef

Fowler JS, Logan J, Volkow ND, Wang GJ. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol. 2005;7:377–87. doi:10.1007/s11307-005-0016-1.PubMedCrossRef

Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science. 1987;235:481–5.PubMedCrossRef

Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37–46. doi:10.2967/jnumed.110.087031.PubMedCrossRef

Hirvonen J, Kailajarvi M, Haltia T, Koskimies S, Nagren K, Virsu P. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85:506–12. doi:10.1038/clpt.2008.241.PubMedCrossRef

Santillo AF, Gambini JP, Lannfelt L, Langstrom B, Ulla-Marja L, Kilander L, et al. In vivo imaging of astrocytosis in Alzheimer’s disease: an (1) (1) C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011;38:2202–8. doi:10.1007/s00259-011-1895-9.PubMedCrossRef

10.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. doi:10.1016/j.jalz.2011.03.003.PubMedCrossRefPubMedCentral

11.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27. doi:10.1016/S1474-4422(10)70223-4.PubMedCrossRef

12.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. doi:10.1016/S1474-4422(14)70090-0.PubMedCrossRef

13.

Bourgeat P, Chetelat G, Villemagne VL, Fripp J, Raniga P, Pike K, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74:121–7. doi:74/2/121 [pii] 10.1212/WNL.0b013e3181c918b5.

14.

Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317–24. doi:10.1002/ana.21955.PubMed

15.

Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770–8. doi:10.1523/JNEUROSCI.3669-09.2009.PubMedCrossRefPubMedCentral

16.

Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C] PIB and [18F] FDG PET study. Neurology. 2007;68:501–8. doi:10.1212/01.wnl.0000244749.20056.d4.PubMedCrossRef

17.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 2006;129:2856–66. doi:10.1093/brain/awl178.PubMedCrossRef

18.

Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta (42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176–83. doi:10.1002/ana.21559.PubMedCrossRefPubMedCentral

19.

Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer’s disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7:56–66. doi: CAR-40 [pii].

20.

La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazizene M. Region-Specific Hierarchy between Atrophy, Hypometabolism, and beta-Amyloid (Abeta) Load in Alzheimer’s Disease Dementia. J Neurosci. 2012;32:16265–73. doi:10.1523/JNEUROSCI.2170-12.2012.PubMedCrossRef

21.

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.PubMedCrossRef

22.

Choo IH, Lee DY, Oh JS, Lee JS, Lee DS, Song IC. Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2010;31:772–9. doi:10.1016/j.neurobiolaging.2008.06.015.PubMedCrossRef

23.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef

24.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–6. doi:10.1111/j.1365-2796.2004.01380.x.PubMedCrossRef

25.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef

26.

Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. doi:10.1002/hbm.10123.PubMedCrossRef

27.

Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid (1–42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673–80.PubMedCrossRef

28.

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231–45. doi:10.1007/BF02815140.PubMedCrossRef

29.

Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49–52. doi:S0304-3940 (00) 01036-3 [pii].

30.

Almkvist O, Tallberg IM. Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer’s disease. Neuropsychology. 2009;23:117–24. doi:10.1037/a0014074.PubMedCrossRef

31.

Bergman I, Blomberg M, Almkvist O. The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol. 2007;48:115–25. doi:10.1111/j.1467-9450.2007.00594.x.PubMedCrossRef

32.

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14. doi:10.1007/s00259-012-2237-2.PubMedCrossRefPubMedCentral

33.

Marutle A, Gillberg PG, Bergfors A, Yu W, Ni R, Nennesmo I. (3) H-deprenyl and (3) H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain. J Neuroinflammation. 2013;10:90. doi:10.1186/1742-2094-10-90.PubMedCrossRefPubMedCentral

34.

Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron. 2008;60:534–42. doi:10.1016/j.neuron.2008.11.007.PubMedCrossRefPubMedCentral

35.

Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743–9. doi:10.1212/01.wnl.0000324924.91351.7d.PubMedCrossRefPubMedCentral

36.

Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63:204–12. doi:10.1002/ana.21223.PubMedCrossRefPubMedCentral

37.

Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719–26. doi:10.1038/nm1058.PubMedCrossRef

38.

Nicoll JA, Weller RO. A new role for astrocytes: beta-amyloid homeostasis and degradation. Trends Mol Med. 2003;9:281–2. doi:10.1016/S1471-4914(03)00109-6.PubMedCrossRef

39.

Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med. 2003;9:453–7.PubMedCrossRef

40.

Nordberg A. Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 2011;3:34. doi:10.1186/alzrt96.PubMedCrossRefPubMedCentral

41.

Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78–87. doi:10.1038/nrneurol.2009.217.PubMedCrossRef

Title: Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients
Authors: IL Han Choo
Stephen F. Carter
Michael L. Schöll
Agneta Nordberg
Publication date: 01-11-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2859-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2014

Erratum to: Do CSF levels of t-Tau, p-Tau and β1–42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease

Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivo

Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma

Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma

Molecular imaging: the emerging role of optical imaging in nuclear medicine

Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology